Share this page on LinkedIn
Share This Page on Google+
Share This Page on Twitter
tell someone about this page print this page
You are here: Contents > 2015 > Volume 24 Number 2 March 2015 > CASE REPORT > Transcatheter Aortic Valve Implantation in a Patient with Myelofibrosis and Severe Thrombocytopenia

Transcatheter Aortic Valve Implantation in a Patient with Myelofibrosis and Severe Thrombocytopenia

Hakan Erkan, Levent Korkmaz, Gülhanım Kırış, Şükrü Çelik

Department of Cardiology, Ahi Evren Cardiovascular and Thoracic Surgery Training and Research Hospital, Trabzon, Turkey

Transcatheter aortic valve implantation (TAVI) has been commonly used to treat patients with aortic stenosis who have a contraindication to, or a high risk of, corrective surgery. Anti-thrombotic treatment is an important part of the TAVI procedure to avoid thrombotic complications during both peri- and post-procedural periods. However, no specific data are available regarding the safety of TAVI with or without anti-thrombotic treatment, either

during the surgical procedure or follow up period in patients with thrombocytopenia, such as myelofibrosis. Here, the case is reported of a patient with myelofibrosis and severe thrombocytopenia who underwent a TAVI procedure without anti-thrombotic treatment such as heparin, acetyl salicylic acid, or clopidogrel.

The Journal of Heart Valve Disease 2014;23:683-687


Transcatheter Aortic Valve Implantation in a Patient with Myelofibrosis and Severe Thrombocytopenia

Click the above hyperlink to view the article, right click (Ctrl click on a Mac) to open in a new browser window or tab.

Purchase this Article

Please click the button below to purchase this article. Single article purchases are provided at $50.00 per article. Upon clicking the button below, single article user account subscription details are requested and, upon successful payment, a single article user account is created. Single articles are availble in your account for seven days after purchase.